Elevated DNMT3A expression is instead linked to hypermethylation of ERα and BRCA1 promoters, resulting in their transcriptional silencing and contributing to tumorigenic processes [83]; furthermore, elevated expression of DNMT3B and BRCA1 epigenetic silencing have been associated with poor survival of BC patients [84]. The gene discussed is DNMT3A; the disease is breast cancer.